AbbVie annual gross profit
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Gross Profit Growth & History (ABBV)
AbbVie's gross profit was $42.96B for fiscal 2025.
View full AbbVie company overviewAbbVie annual gross profit history
| Fiscal year | Period ended | Gross profit | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $42.96B | $3.53B | +8.94% |
| 2024 | 2024-12-31 | $39.43B | $5.53B | +16.30% |
| 2023 | 2023-12-31 | $33.90B | −$6.74B | −16.58% |
| 2022 | 2022-12-31 | $40.64B | $1.89B | +4.87% |
| 2021 | 2021-12-31 | $38.75B | $8.33B | +27.40% |
| 2020 | 2020-12-31 | $30.42B | $4.59B | +17.77% |
| 2019 | 2019-12-31 | $25.83B | $792.0M | +3.16% |
| 2018 | 2018-12-31 | $25.04B | $3.86B | +18.23% |
| 2017 | 2017-12-31 | $21.17B | $1.37B | +6.91% |
| 2016 | 2016-12-31 | $19.81B | $1.45B | +7.88% |
| 2015 | 2015-12-31 | $18.36B | $2.83B | +18.19% |
| 2014 | 2014-12-31 | $15.53B | $1.32B | +9.33% |
| 2013 | 2013-12-31 | $14.21B | $337.0M | +2.43% |
| 2012 | 2012-12-31 | $13.87B | $1.07B | +8.33% |
| 2011 | 2011-12-31 | $12.80B | — | — |
AbbVie quarterly gross profit
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross profit | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.70B | $1.62B | +14.64% |
| Q1 2026 | 2026-03-31 | $10.78B | $1.44B | +15.45% |
| Q4 2025 | 2025-12-31 | $12.07B | $1.36B | +12.70% |
| Q3 2025 | 2025-09-30 | $10.47B | $224.0M | +2.19% |
| Q2 2025 | 2025-06-30 | $11.08B | $817.0M | +7.96% |
| Q1 2025 | 2025-03-31 | $9.34B | $1.13B | +13.69% |
| Q4 2024 | 2024-12-31 | $10.71B | $2.11B | +24.53% |
| Q3 2024 | 2024-09-30 | $10.25B | $2.81B | +37.70% |
| Q2 2024 | 2024-06-30 | $10.26B | $635.0M | +6.60% |
| Q1 2024 | 2024-03-31 | $8.22B | −$23.0M | −0.28% |
| Q4 2023 | 2023-12-31 | $8.60B | −$2.35B | −21.50% |
| Q3 2023 | 2023-09-30 | $7.44B | −$2.35B | −23.98% |
| Q2 2023 | 2023-06-30 | $9.63B | −$788.0M | −7.57% |
| Q1 2023 | 2023-03-31 | $8.24B | −$1.25B | −13.15% |
| Q4 2022 | 2022-12-31 | $10.95B | $385.0M | +3.64% |
| Q3 2022 | 2022-09-30 | $9.79B | −$162.0M | −1.63% |
| Q2 2022 | 2022-06-30 | $10.41B | $977.0M | +10.35% |
| Q1 2022 | 2022-03-31 | $9.49B | $689.0M | +7.83% |
| Q4 2021 | 2021-12-31 | $10.57B | $1.39B | +15.17% |
| Q3 2021 | 2021-09-30 | $9.95B | $2.10B | +26.74% |
| Q2 2021 | 2021-06-30 | $9.44B | $2.72B | +40.54% |
| Q1 2021 | 2021-03-31 | $8.80B | $2.12B | +31.75% |
| Q4 2020 | 2020-12-31 | $9.17B | $2.48B | +36.97% |
| Q3 2020 | 2020-09-30 | $7.85B | $1.29B | +19.71% |
| Q2 2020 | 2020-06-30 | $6.71B | $278.0M | +4.32% |
| Q1 2020 | 2020-03-31 | $6.68B | $543.0M | +8.85% |
| Q4 2019 | 2019-12-31 | $6.70B | $415.0M | +6.61% |
| Q3 2019 | 2019-09-30 | $6.56B | $158.0M | +2.47% |
| Q2 2019 | 2019-06-30 | $6.44B | $92.0M | +1.45% |
| Q1 2019 | 2019-03-31 | $6.13B | $127.0M | +2.11% |
| Q4 2018 | 2018-12-31 | $6.28B | $825.0M | +15.12% |
| Q3 2018 | 2018-09-30 | $6.40B | $1.02B | +19.00% |
| Q2 2018 | 2018-06-30 | $6.34B | $929.0M | +17.16% |
| Q1 2018 | 2018-03-31 | $6.01B | $1.08B | +22.04% |
| Q4 2017 | 2017-12-31 | $5.46B | $217.0M | +4.14% |
| Q3 2017 | 2017-09-30 | $5.38B | $451.0M | +9.15% |
| Q2 2017 | 2017-06-30 | $5.42B | $368.0M | +7.29% |
| Q1 2017 | 2017-03-31 | $4.92B | $333.0M | +7.26% |
| Q4 2016 | 2016-12-31 | $5.24B | $316.0M | +6.42% |
| Q3 2016 | 2016-09-30 | $4.93B | $151.0M | +3.16% |
| Q2 2016 | 2016-06-30 | $5.05B | $488.0M | +10.70% |
| Q1 2016 | 2016-03-31 | $4.59B | $491.0M | +11.98% |
| Q4 2015 | 2015-12-31 | $4.92B | $592.0M | +13.66% |
| Q3 2015 | 2015-09-30 | $4.78B | $852.0M | +21.71% |
| Q2 2015 | 2015-06-30 | $4.56B | $746.0M | +19.56% |
| Q1 2015 | 2015-03-31 | $4.10B | $635.0M | +18.34% |
| Q4 2014 | 2014-12-31 | $4.33B | $504.0M | +13.16% |
| Q3 2014 | 2014-09-30 | $3.92B | $359.0M | +10.07% |
| Q2 2014 | 2014-06-30 | $3.81B | $175.0M | +4.81% |
| Q1 2014 | 2014-03-31 | $3.46B | $287.0M | +9.04% |
| Q4 2013 | 2013-12-31 | $3.83B | −$112.0M | −2.84% |
| Q3 2013 | 2013-09-30 | $3.57B | $72.0M | +2.06% |
| Q2 2013 | 2013-06-30 | $3.64B | $218.0M | +6.37% |
| Q1 2013 | 2013-03-31 | $3.18B | $159.0M | +5.27% |
| Q4 2012 | 2012-12-31 | $3.94B | — | — |
| Q3 2012 | 2012-09-30 | $3.49B | — | — |
| Q2 2012 | 2012-06-30 | $3.42B | — | — |
| Q1 2012 | 2012-03-31 | $3.02B | — | — |
AbbVie gross profit trends
Over the last five fiscal years, AbbVie's gross profit increased from $30.42B to $42.96B, a change of $12.54B. The latest reported quarter, Q2 2026, shows $12.70B.
About the metric
What gross profit means
Gross profit is the amount of revenue remaining after the direct costs of producing and delivering a company’s goods or services. It helps show the dollars available to cover operating expenses before operating income, interest, and taxes.
Calculation and source
SEC-reported and calculated gross profit
TickerStat uses gross profit reported in company SEC filings when available. Otherwise, it calculates gross profit as SEC-reported revenue minus aligned cost of revenue for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...